Valeant Pharmaceuticals International Inc. is under investigation by the U.S. Securities and Exchange Commission in a previously undisclosed probe, the company said.

The SEC probe is separate from an existing investigation into a company purchased by Valeant last year, Salix Pharmaceuticals Ltd., said a person familiar with the matter. The Salix probe was disclosed previously. The person declined to comment on the record because the matter isn’t yet public. It’s unclear what the new probe is centered around.

“Valeant confirms that it has several ongoing investigations, including investigations by the U.S. Attorney’s Offices for Massachusetts and the Southern District of New York, the SEC, and Congress,” said Laurie Little, a Valeant spokeswoman.

Judy Burns, an SEC spokeswoman, declined to comment on the new probe.